12:00 AM
Apr 22, 2013
 |  BC Week In Review  |  Company News  |  Deals

Elan, Royalty Pharma deal

Elan used $1 billion to repurchase 88.9 million shares, or about 14.8%, at $11.25 in a Dutch auction. The price was at the low end of the company's $11.25-$13 proposed range and is a 2% discount to Elan's close of $11.42 on March 7, the day before the auction was announced. Elan repurchased about 82 million shares tendered by its largest shareholder,...

Read the full 290 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >